Webinar on recent adjunctive antiseizure medications with an emphasis on the use of cenobamate for focal epilepsies and fenfluramine for Dravet syndrome. Read More
Latest News
Treatment discontinuation in MS: the DOT-MS trial
May 5, 2025The newly-published Discontinuing Disease-modifying Therapies in Stable Relapsing-onset Multiple Sclerosis (DOT-MS) is the second important trial to examine the feasibility of discontinuing disease-modifying therapy (DMT) in patients with multiple sclerosis (Coerver et al. JAMA Neurol 2025;82:123-131). Read More
CLINICAL CASES IN MS: A 24 Y.O. WOMAN WITH PARESTHESIAE AND NON-ENHANCING LESIONS
April 25, 2025Click here to watch Dr. Lisa Sabella discuss the case and the responses to the survey.
R.M. is a 24-year-old woman who works at a daycare centre. She is referred from the emergency room because of a two-week history of paresthesiae in both legs and the mid and lower trunk. She is not aware of any weakness. There is no bladder disturbance. She has a subjective mid truncal sensory level. Prior history includes a Bell’s palsy three years ago which was painless and resolved without treatment in 3-4 weeks. Read More
AAN 2025 – report on fluid biomarkers in MS
April 22, 2025SPECIAL REPORT
The following summarizes some of the key data on biomarkers from the American Academy of Neurology annual meeting (AAN), San Diego, CA, April 5-9, 2025.
Neurofilament-light chain (NfL)
Combining sNfL and GFAP
Kappa free light chain
Read More